Вплив інгібіторів ароматази третього покоління на окремі компоненти перебігу експериментального метаболічного синдрому

Abstract

Introduction. Nowadays, about 86 % among patients with metabolic syndrome have serious disorder of glucose tolerance and about 60 % of them suffer from visceral obesity. Moreover in many worldwide studies it was shown that these pathogenetic manifestations of the metabolic syndrome had a significant correlation with the imbalance of sex hormones.The aim of the study – to learn the effect of third-generation aromatase inhibitors on the parameters of insulin resistance and visceral obesity in hamsters with the experimental metabolic syndrome.Research Methods. The insulin level in the hamster`s blood serum was measured by the enzyme immunoassay method, and the glucose level by the electrochemical method. The mass coefficients of anatomical fragments of adipose tissue were calculated to estimate visceral obesity. The results were processed by using the Mann-Whitney U-test and the 4Pl method.Results and Discussion. All studied drugs, in varying degrees, influenced on the pathogenetic components of the experimental metabolic syndrome. Exemestane was demonstrated the greatest effectiveness in reducing parameter of the insulin resistance by, butletrozole – in decreasing of visceral obesity ratio.Сonclusion. Romatase inhibitors can become promising drugs for correcting the pathogenetic components of the metabolic syndrome, in particular insulin resistance and visceral obesity.